Sodium hyaluronate as a carrier for intravitreal gentamicin. An experimental study.
Fifty mcg of gentamicin was combined with saline or with 0.8% sodium hyaluronate and injected into the vitreous cavity of rabbit eyes with moderate to severe Staphylococcus aureus endophthalmitis. Endophthalmitis was controlled in 9 of 10 eyes. There was no evidence of toxicity with either treatment regimen. Although the clearance study demonstrated statistical differences at all time points studied, the half-lives of both treatment regimens were similar (3.3 h for aqueous gentamicin and 3.6 h for sodium hyaluronate/gentamicin). These results suggest that the vitreous played a role in keeping the aqueous gentamicin in the eye for a longer time, as similar half-lives were shown with both types of treatment. Thus, if a vitrectomy has to be done for the treatment of endophthalmitis, as much as possible of the vitreous should be left in situ to maintain the drug for longer periods in the eye. Also, if it is necessary to remove all vitreous during vitrectomy, it may be more effective to administer the drug with sodium hyaluronate so as to prolong its action inside the eye.
Moreira
C A
CA
Department of Ophthalmology, Doheny Eye Institute, Los Angeles, CA.
Armstrong
D K
DK
Jelliffe
R W
RW
Moreira
A T
AT
Woodford
C C
CC
Liggett
P E
PE
Trousdale
M D
MD
D000818:Animals; D001035:Aphakia / Q000378:metabolism; D004337:Drug Carriers; D009877:Endophthalmitis / Q000188:drug therapy*; D005839:Gentamicins / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity; D006820:Hyaluronic Acid; D011817:Rabbits; D012160:Retina / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D014821:Vitrectomy; D014822:Vitreous Body / Q000187:drug effects / Q000378:metabolism
D004337:Drug Carriers; D005839:Gentamicins; D006820:Hyaluronic Acid